Sage Therapeutics Inc. (NASDAQ:SAGE)’s share price gapped up prior to trading on Thursday . The stock had previously closed at $43.15, but opened at $43.20. Sage Therapeutics shares last traded at $43.90, with a volume of 265,001 shares trading hands.

Several equities analysts recently commented on the company. BMO Capital Markets reissued a “buy” rating on shares of Sage Therapeutics in a report on Tuesday, July 12th. Chardan Capital assumed coverage on Sage Therapeutics in a report on Tuesday, May 24th. They issued a “sell” rating and a $18.00 target price on the stock. Leerink Swann reissued a “buy” rating and issued a $66.00 target price on shares of Sage Therapeutics in a report on Tuesday, July 12th. HC Wainwright assumed coverage on Sage Therapeutics in a report on Thursday, June 23rd. They issued a “buy” rating and a $56.00 target price on the stock. Finally, William Blair reissued an “outperform” rating and issued a $75.00 target price on shares of Sage Therapeutics in a report on Friday, July 15th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and nine have issued a buy rating to the company’s stock. Sage Therapeutics has a consensus rating of “Buy” and an average price target of $66.18.

The firm has a 50 day moving average of $33.88 and a 200 day moving average of $34.59. The firm’s market capitalization is $1.42 billion.

Sage Therapeutics (NASDAQ:SAGE) last posted its earnings results on Thursday, May 5th. The biopharmaceutical company reported ($0.97) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.98) by $0.01. Analysts expect that Sage Therapeutics Inc. will post ($4.34) EPS for the current fiscal year.

In related news, CFO Kimi Iguchi sold 5,000 shares of Sage Therapeutics stock in a transaction on Tuesday, July 12th. The shares were sold at an average price of $49.55, for a total transaction of $247,750.00. Following the sale, the chief financial officer now owns 83,739 shares of the company’s stock, valued at approximately $4,149,267.45. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Albert Robichaud sold 22,000 shares of Sage Therapeutics stock in a transaction on Tuesday, July 12th. The stock was sold at an average price of $40.00, for a total transaction of $880,000.00. Following the sale, the insider now directly owns 140,222 shares in the company, valued at approximately $5,608,880. The disclosure for this sale can be found here.

Several large investors recently added to or reduced their stakes in the company. Nationwide Fund Advisors increased its stake in Sage Therapeutics by 9.4% in the fourth quarter. Nationwide Fund Advisors now owns 21,143 shares of the biopharmaceutical company’s stock valued at $1,233,000 after buying an additional 1,816 shares during the last quarter. California State Teachers Retirement System increased its stake in Sage Therapeutics by 1.6% in the fourth quarter. California State Teachers Retirement System now owns 25,578 shares of the biopharmaceutical company’s stock valued at $1,491,000 after buying an additional 400 shares during the last quarter. ProShare Advisors LLC increased its stake in Sage Therapeutics by 8.2% in the fourth quarter. ProShare Advisors LLC now owns 25,219 shares of the biopharmaceutical company’s stock valued at $1,470,000 after buying an additional 1,919 shares during the last quarter. GAM Holding AG increased its stake in Sage Therapeutics by 74.1% in the fourth quarter. GAM Holding AG now owns 79,400 shares of the biopharmaceutical company’s stock valued at $4,629,000 after buying an additional 33,800 shares during the last quarter. Finally, BB Biotech AG bought a new stake in Sage Therapeutics during the fourth quarter valued at $41,315,000.

SAGE Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing medicines to treat life-threatening, rare central nervous system (CNS) disorders. The Company’s lead product candidate in its status epilepticus (SE) program is SAGE-547. SAGE-689 and SAGE-217 are two additional product candidates in its pipeline.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.